Candel Therapeutics, Inc.

NASDAQ•CADL

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-07-27

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Contact Information

117 Kendrick Street, Suite 450, Needham, MA, 02494, United States

617-916-5445

www.candeltx.com

Market Cap

$282.74M

P/E (TTM)

-7.4

Dividend Yield

52W High

$7.25

52W Low

$4.34

52W Range

28%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.54+0.00%

4-Quarter Trend

FCF

-$10.98M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Narrows Significantly Net loss decreased $16,995 K to $(38,182) K for 2025, reflecting reduced warrant liability impact.

Aglatimagene Prostate Success Phase 3 DFS endpoint met for aglatimagene plus radiation (HR 0.70); median DFS not reached.

R&D Investment Increases Research and development expenses increased $11.18M to $30.50M, driven by clinical trial manufacturing costs.

Cash Position Strengthened Cash and equivalents totaled $119.73M by year-end 2025, supported by recent financing activities.

Risk Factors

Substantial Funding Required Need substantial additional funding; inability to raise capital forces program delays, reductions, or cessation of operations.

No Product Sales Revenue Limited operating history; no revenue generated from product sales; expecting continued operating losses for foreseeable future.

Clinical Trial Success Dependency Business success depends on clinical trials adequately demonstrating safety and efficacy for aglatimagene and linoserpaturev.

Unpredictable Regulatory Approval Regulatory approval processes are lengthy, complex, and inherently unpredictable, potentially impairing revenue generation.

Outlook

Prostate BLA Submission Planned Ongoing dialogue with FDA for aglatimagene BLA submission in prostate cancer targeted for fourth quarter of 2026.

NSCLC Phase 3 Trial Launch Plan to initiate pivotal phase 3 trial for metastatic NSCLC patients resistant to ICI treatment in second quarter of 2026.

Cash Runway Extended Existing cash plus 2026 Follow-On Offering proceeds expected to fund operations into the first quarter of 2028.

Biomarker Data Presentation Expect to present novel immunological biomarker data in localized prostate cancer patients during third quarter of 2026.

Peer Comparison

Revenue (TTM)

EDIT

$40.52M

+25.4%

PRQR

$17.94M

-15.9%

IMMP

$8.35M

+121.2%

Gross Margin (Latest Quarter)

EDIT

100.0%

+2621.3pp

ACIU

100.0%

+0.0pp

PRQR

85.5%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CAPR	$1.60B	-16.3	-67.5%	5.9%
DRTS	$693.52M	-15.8	-57.3%	12.9%
CTNM	$494.70M	-6.8	-30.1%	3.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 7, 2026

EPS:-$0.31

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data